The antibody–drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and overall survival, leading to FDA approval and a new treatment option for patients.

ASCO 2024: Corbus, reporting on early trials of its antibody-drug conjugate, says it "seems to be clinically effective in bladder cancer." ...

For patients with cervical cancer, the results were, respectively, 43% and 86%. All tumor types at doses ≥ 2.7 mg/Kg resulted in 40% ORR and 73% DCR.

ADRX-0706 is a Nectin-4 ADC being evaluated in the Phase 1b portion of an ongoing Phase 1a/b clinical trial (NCT06036121) for the treatment of select advanced solid tumors, including cervical cancer.

Among patients with Nectin-4 IHC 3+, the ORR was 43.6%. The results of the above studies indicate that 9MW2821 has a positive therapeutic effect in patients with cervical cancer.

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...